2003•Unpublished venueRequires access

Clinical Considerations in the Use of Pyridostigmine Bromide as Pretreatment for Nerve-Agent Exposure

James M. Madsen, Charles G. Hurst, Roger MacIntosh, James A. Romano, Jr.

Abstract

Destroy this report when no longer needed. Do not return to the originator. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Army or the Department of Defense. In conducting the research described in this report, the investigators adhered to the Guide for

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Pyridostigmine Bromide, Nerve agent, Navy, Pyridostigmine, Medicine, Pharmacokinetics, Pharmacology, Chemistry